CervoMed Inc. presented the first placebo‑controlled magnetic resonance imaging (MRI) evidence that its lead candidate, neflamapimod, increases basal forebrain volume and improves functional connectivity in patients with dementia with Lewy bodies (DLB). The data were disclosed at the 2026 American Academy of Neurology Annual Meeting in Chicago.
The RewinD‑LB Phase 2b trial, which enrolled 159 DLB patients in a 16‑week double‑blind, placebo‑controlled design, showed a 3.5 % increase in right‑sided basal forebrain volume in the neflamapimod group versus a 4.2 % decrease in the placebo group (p = 0.028). Functional connectivity between the basal forebrain and the default mode network improved by 46 % (p = 0.019) in the treatment arm, providing the first objective biomarker of disease‑modifying activity in this population.
The imaging data were analyzed by a blinded team at Amsterdam University Medical Center and presented by Dr. Menno Schoonheim, Scientific Director of the MS Center, and by CervoMed’s CEO, Dr. John Alam. The findings support the company’s hypothesis that neflamapimod can reverse synaptic dysfunction and neuronal shrinkage in the cholinergic system that drives DLB progression.
CervoMed’s announcement marks a significant step toward demonstrating disease‑modifying activity for its single‑asset program. The MRI evidence could accelerate regulatory review and strengthen the case for a pivotal Phase 3 trial, which the company plans to launch later in 2026 if additional financing is secured.
Financially, CervoMed reported a Q4 2025 net loss of $0.88 per share and revenue of $0.01 million, a 99.5 % decline from the prior year. The company’s cash position was $35.2 million as of March 31 2025, expected to fund operations into mid‑2026. The Phase 3 trial’s feasibility therefore hinges on securing new capital.
In a statement, Dr. Alam said, “The significant improvements compared to placebo in change in CDR‑SB observed in the within‑subject comparison, along with correlated reductions in a key biomarker of neurodegeneration further strengthen our confidence in neflamapimod’s potential as a treatment for DLB.”
CervoMed, formerly EIP Pharma, merged with Diffusion Pharmaceuticals in August 2023 and remains a single‑asset biopharma focused on neflamapimod. With no approved disease‑modifying therapies for DLB, the company’s clinical milestones are critical for establishing a therapeutic niche and attracting future investment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.